✦ LIBER ✦

Group comparative trial of 2% sodium cromoglycate (Opticrom) with placebo in the treatment of seasonal allergic conjunctivitis

✍ Scribed by A. C. M. LINDSAY-MILLER

Book ID: 108682683
Publisher: John Wiley and Sons
Year: 1979
Tongue: English
Weight: 239 KB
Volume: 9
Category: Article
ISSN: 0954-7894
DOI: 10.1111/j.1365-2222.1979.tb01553.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Double-blind group comparative study of

Double-blind group comparative study of 2% nedocromil sodium eye drops with 2% sodium cromoglycate and placebo eye drops in the treatment of seasonal allergic conjunctivitis

✍ M. LEINO; K. ENNEVAARA; A.-L. LATVALA; P. NORDGREN; A.-M. POSTI; R. SUVES; E. TA 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 372 KB

Two mast cell stabilizers, pemirolast po

Two mast cell stabilizers, pemirolast potassium 0.1% and nedocromil sodium 2%, in the treatment of seasonal allergic conjunctivitis: A comparative study

✍ David G. Shulman 📂 Article 📅 2003 🏛 Springer Healthcare Communications 🌐 English ⚖ 108 KB

Efficacy and safety of bilastine 20 mg c

Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study

✍ P. Kuna; C. Bachert; Z. Nowacki; P. Van Cauwenberge; I. Agache; L. Fouquert; A. 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 209 KB

Subcutaneous interleukin-2 and interfero

Subcutaneous interleukin-2 and interferon α in the treatment of patients with metastatic renal cell carcinoma—Less efficacy compared with intravenous interleukin-2 and interferon α : Results of a multicenter Phase II trial from the Groupe Français d'Immunothérapie

✍ Alain Ravaud; Rémy Delva; Fréderic Gomez; Christine Chevreau; Jean-Yves Douillar 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB 👁 1 views

## Background: The main objective of this trial was to evaluate the combination of subcutaneous (sc) interleukin-2 (il-2) with interferon alpha-2a (ifn-alpha) in the treatment of patients with metastatic renal cell carcinoma (mrcc) compared with a previous trial that used continuous-infusion il-2 a